Cero Therapeutics provides update on Phase 1 trial of CER-1236

CERo Therapeutics (CERO) announces a key clinical update from the Company’s ongoing CertainT-1 trial focused on patients with acute myeloid leukemia. Following completion of the dose-limiting toxicity observation period for the first cohort, investigators observed cell expansion with no CRS, ICANS, or treatment-related adverse events reported to date. Expansion was seen with or without lymphodepletion. Investigators gave four rounds of CER-1236 cells to the second patient enrolled, with myelodysplastic syndrome that progressed to AML with an inv3 chromosome translocation. A 61-day platelet transfusion-free interval was observed after CER-1236 treatment, exceeding a commonly referenced 8-week benchmark cited in clinical studies in the context of platelet transfusion independence. Transfusion independence ended following a subsequent round of lymphodepleting chemotherapy plus CER-1236 treatment.